DRUG · Unmapped registry intervention
Rigosertib
Find medicine records ·
Find other trials using this name
Clinical trial
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
NCT04263090
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Nivolumab
Normalized identity: nivolumabView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedRigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Adenocarcinomaverified · MONDO: adenocarcinoma
Stage IVunresolved
Interventions
RigosertibDRUG
NivolumabDRUG · verified · RxNorm: nivolumab
Sponsors & collaborators
Icahn School of Medicine at Mount Sinailead sponsor
Bristol-Myers Squibbcollaborator
Traws Pharma, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04263090 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.